Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado 80045-6511, USA.
J Clin Endocrinol Metab. 2011 Jul;96(7):2154-62. doi: 10.1210/jc.2010-2964. Epub 2011 May 11.
Autoimmune Addison's disease (AD) is the major cause of primary adrenal failure in developed nations. Autoantibodies to 21-hydroxylase (21OH-AA) are associated with increased risk of progression to AD. Highest genetic risk is associated with the Major Histocompatibility region (MHC), specifically human leukocyte antigen (HLA)-DR3 haplotypes (containing HLA-B8) and HLA-DR4.
The objective of the study was the further characterization of AD risk associated with MHC alleles.
DESIGN, SETTING, AND PARTICIPANTS: MHC genotypes were determined for HLA-DRB1, DQA1, DQB1, MICA, HLA-B, and HLA-A in 168 total individuals with 21OH-AA (85 with AD at referral and 83 with positive 21OH-AA but without AD at referral).
MAIN OUTCOME MEASURE(S): Genotype was evaluated in 21OH-AA-positive individuals. Outcomes were compared with general population controls and type 1 diabetes patients.
In HLA-DR4+ individuals, HLA-B15 was found in only one of 55 (2%) with AD vs. 24 of 63 (40%) 21OH-AA-positive nonprogressors (P = 2 × 10(-7)) and 518 of 1558 (33%) HLA-DR4 patients with type 1 diabetes (P = 1 × 10(-8)). On prospective follow-up, none of the HLA-B15-positive, 21-hydroxylase-positive individuals progressed to AD vs. 25% non-HLA-B15 autoantibody-positive individuals by life table analysis (P = 0.03). Single nucleotide polymorphism analysis revealed the HLA-DR/DQ region associated with risk and HLA-B15 were separated by multiple intervening single-nucleotide polymorphism haplotypes.
HLA-B15 is not associated with protection from 21OH-AA formation but is associated with protection from progression to AD in 21OH-AA-positive individuals. To our knowledge, this is one of the most dramatic examples of genetic disease suppression in individuals who already have developed autoantibodies and of novel dominant suppression of an autoimmune disease by a class I HLA allele.
自身免疫性艾迪生病(Addison's disease,AD)是发达国家原发性肾上腺功能衰竭的主要原因。21-羟化酶(21OH-AA)自身抗体与向 AD 进展的风险增加相关。最高的遗传风险与主要组织相容性复合体(MHC)相关,特别是人类白细胞抗原(HLA)-DR3 单倍型(包含 HLA-B8)和 HLA-DR4。
本研究的目的是进一步描述与 MHC 等位基因相关的 AD 风险。
设计、地点和参与者:对 168 名 21OH-AA 阳性个体(85 名在就诊时患有 AD,83 名在就诊时 21OH-AA 阳性但无 AD)的 HLA-DRB1、DQA1、DQB1、MICA、HLA-B 和 HLA-A 的 MHC 基因型进行了确定。
在 21OH-AA 阳性个体中评估了基因型。将结果与一般人群对照和 1 型糖尿病患者进行了比较。
在 HLA-DR4+个体中,仅在 55 名 AD 患者中的 1 名(2%)中发现 HLA-B15,而在 63 名 21OH-AA 阳性非进展者中的 24 名(40%)(P = 2×10(-7))和在 1558 名 1 型糖尿病患者中的 518 名(33%)(P = 1×10(-8))中发现 HLA-B15。在前瞻性随访中,通过生命表分析,没有一名 HLA-B15 阳性、21-羟化酶阳性的个体进展为 AD,而在非 HLA-B15 自身抗体阳性的个体中,25%进展为 AD(P = 0.03)。单核苷酸多态性分析显示,与风险相关的 HLA-DR/DQ 区域与 HLA-B15 分离,后者由多个中间单核苷酸多态性单倍型隔开。
HLA-B15 与 21OH-AA 形成的保护无关,但与 21OH-AA 阳性个体向 AD 进展的保护有关。据我们所知,这是已经产生自身抗体的个体中遗传疾病抑制和一种 I 类 HLA 等位基因对自身免疫性疾病的新型显性抑制的最显著例子之一。